Sign In
Buy HZNP
$116.30
+0 (+0%)
At Close: Jan 04, 2024
Is Horizon Therapeutics (HZNP) a Great Growth Stock?
10:06am, Friday, 13'th Aug 2021
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Horizon Therapeutics (HZNP).
Horizon Therapeutics Will Offer Above Average Returns
03:17pm, Thursday, 12'th Aug 2021
Horizon Therapeutics has now reached a growth point that is supportive of long-term success due to multiple eggs in the basket.
Horizon's (HZNP) Q2 Earnings and Revenues Beat, Stock Up
03:13pm, Thursday, 05'th Aug 2021
Horizon (HZNP) beats on both earnings and revenues in Q2. Sales soared on account of the relaunch of the thyroid eye disease drug Tepezza.
Horizon Therapeutics Public Limited Company (HZNP) CEO Tim Walbert on Q2 2021 Results - Earnings Call Transcript
12:00pm, Wednesday, 04'th Aug 2021
Horizon Therapeutics Public Limited Company (HZNP) CEO Tim Walbert on Q2 2021 Results - Earnings Call Transcript
Horizon Therapeutics Stock Shoots Higher As Relaunch Of Thyroid Eye Disease Med Boosts Q2 Sales; Raises FY21 Outlook
11:45am, Wednesday, 04'th Aug 2021
Horizon Therapeutics plc (NASDAQ: HZNP) stock is gaining amid second-quarter solid earnings after reporting adjusted EPS of $1.62, almost tripled from $0.40 posted a year ago, and easily beating the
Horizon Therapeutics (HZNP) Q2 Earnings and Revenues Beat Estimates
09:55am, Wednesday, 04'th Aug 2021
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 78.02% and 17.76%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Horizon Therapeutics: Q2 Earnings Insights
08:08am, Wednesday, 04'th Aug 2021
Shares of Horizon Therapeutics (NASDAQ:HZNP) moved higher by 9.0% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 305.00% year over year to $1
10 Promising Stocks to Buy That Are Getting Lots of Analyst Love
04:44pm, Friday, 30'th Jul 2021
Analysts' reports can be an easy way to gauge market sentiment, particularly if you are confused regarding which stocks to buy. The post 10 Promising Stocks to Buy That Are Getting Lots of Analyst Lov
Horizon (HZNP) Begins Phase II Study for Lupus Candidate
11:48am, Wednesday, 30'th Jun 2021
Horizon (HZNP) starts phase II study to evaluate HZN-7734, an antibody to treat systemic lupus, which is an autoimmune disease wherein the immune system mistakenly attacks healthy cells and tissues.
This Therapeutics Company Is Eyeing Zero Competition for the Next 5 Years
06:15am, Wednesday, 30'th Jun 2021
If production setbacks can be avoided, gains should be in sight.
Horizon Acquires Rights to Arrowhead's RNAi-Based Gout Treatment Candidate
11:35am, Monday, 21'st Jun 2021
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) and Horizon Therapeutics plc (NASDAQ: HZNP) have entered into a global collaboration and license agreement for ARO-XDH for uncontrolled gout. Horizon
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of company information on Neuromyelitis Optica Spectrum Disorder (NMOSD) in three oral sessions during
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in the ADVANCE trial evaluating the concomitant use of KRYSTEXXA (pegloticase injection)
Horizon Therapeutics: Tepezza Relaunch Off To A Strong Start
01:41pm, Tuesday, 25'th May 2021
Horizon's Q1 2021 results were good considering Tepezza's supply disruption. Tepezza sales resumed in early Q1 and it is off to a strong start with record patient enrollment forms in April.
Horizon Therapeutics plc Ranked #1 in Overall Corporate Reputation Among U.S. Patient Groups that Report Working with the Company
11:30am, Thursday, 13'th May 2021
DUBLIN--(BUSINESS WIRE)--Horizon ranked #1 in overall corporate reputation among U.S. patient groups that reported working with the company.
